Volume : 6, Issue : 1, January - 2017

THE ROLE OF INTRAVENOUS MAGNESIUM IN REDUCING SHORT TERM MORTALITY OF ACUTE MYOCARDIAL INFARCTION AS COMPARED TOSTREPTOKINASE AND PLACEBO.

Dr. Kuldeep Saini, Dr. Kanta Bhati, Dr. A. Sulemani, Dr. Ajay. B. R.

Abstract :

<p>&nbsp;<span style="font-size: 14pt; text-align: justify;">In a randomized control trial of 84 patients of acute myocardial infarction who were divided into 3 therapeutic groups randomly i.e. magnesium treated group, streptokinase treated group and placebo group. The number of patients were 28 in each group. Each group compared in reference of mortality, complications and serum magnesium levels of post myocardial infarction period of 28 days.</span><span style="font-size: 14pt; text-align: justify;">&nbsp; </span><span style="font-size: 14pt; text-align: justify;">Significant hypomagnecemia was present in all cases of acute myocardial infarction on the day of admission in CCU. During the 28 days, mortality was 2(7.14%) in magnesium and streptokinase treated group and 3(10.71%) in placebo group. In magnesium treated group least number of arrhythmiaSwere observed 10(17.8%), while in other two study groups</span><span style="font-size: 14pt; text-align: justify;">&nbsp; </span><span style="font-size: 14pt; text-align: justify;">number of arrhythmia were observed 11 (39.28%) in each group. We also observed that, least number of pump failure in magnesium treated group. No adverse effect of intravenous magnesium were observed. This study conclude that all the cases of acute myocardial infarction should be given IV magnesium soon after admission in CCU, as this is cheap and safe drug which can reduce short term complications and mortality after acute myocardial infarction.</span></p> <p class="MsoNormal" style="text-align:justify;line-height:200%"><span class="FontStyle20"><span style="font-size:14.0pt;line-height:200%"><o:p></o:p></span></span></p>